Dimerix (ASX:DXB) DMX-700 Study Shows Significant 80% Reduction in Lung Injury – The Market Herald

0

Subscribe to

Be the first with the news that moves the market

  • Dimerix (DXB) announces results from its pipeline program’s DMX-700 study, which indicate a significant 80 percent reduction in lung injury in mice
  • The study presented “very encouraging and statistically significant” pre-clinical data strongly supporting further development of DMX-700
  • Additional intellectual property is being identified and an additional patent application is pending
  • The clinical study is now being designed along with any additional non-clinical safety studies required, with the first clinical study expected to begin in the first half of 2023
  • Dimerix shares are up 20 percent and are trading at 15 cents as of 12:16pm AEST

Dimerix (DXB) has released results from its pipeline program’s DMX-700 study, which indicate a significant 80 percent reduction in lung injury in mice.

DMX-700 has been identified as a novel oral candidate for the treatment of chronic obstructive pulmonary disease (COPD) using Dimerix’ proprietary Receptor-HIT platform.

The study presented “very encouraging and statistically significant” preclinical data that strongly support the advancement of DMX-700 tested in mice with oral administration in the porcine pancreatic elastase (PPE) model of COPD.

The PPE model is the most commonly used COPD model because it mimics the inflammatory response in the lungs of mice and leads to lung tissue breakdown and respiratory distress.

CEO and Managing Director Nina Webster said the information should greatly encourage clinical investigators and patients in the company’s clinical trials of DMX-700.

“We found that simultaneously blocking the known targets of COPD with DMX-700 resulted in a statistically significant reduction in lung damage that leads to fibrosis, or scarring,” said Dr. Webster.

“Our now growing clinical pipeline will strengthen our ongoing discussions with potential commercial and strategic partners.”

Additional intellectual property has been identified and an additional patent application is pending.

The DMX-700 compounds individually have a known safety profile in human studies, which means DMX-700 may have the potential to flow directly into clinical trials, subject to regulatory approvals.

The clinical study is now being designed along with any additional non-clinical safety studies required, with the first clinical study expected to begin in the first half of 2023.

Dimerix shares are up 20 percent, trading at 15 cents as of 12:16pm AEST.

Share.

Comments are closed.